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CASE REPORT
Recombinant human growth hormone (GH) is
an important pharmacologic agent to stimulate
linear growth and improve body composition in
children with GH deficiency (GHD), chronic
renal failure, Turner syndrome, Prader-Willi syn-
drome (PWS), and children born small for ges-
tational age.1 The action of GH via its receptors
involves many organ systems and metabolic path-
ways. This diverse action may induce untoward ef-
fects of GH therapy during growth promotion.
Established and potential side effects of GH are
intracranial hypertension, edema, slipped capital
femoral epiphysis (SCFE), worsening of scoliosis,
gynecomastia, hyperglycemia, and malignancy.1–3
Previous reports suggested that the prevalence 
of SCFE increased in children treated with GH.2–5
Here, we report three patients who developed
SCFE during GH therapy. To our knowledge, this
complication of GH therapy has not been previ-
ously reported in Taiwan.
Case Reports
Case 1
A 27-year-old man was noted to have short stat-
ure at the age of 4 years. He had a growth rate of
less than 4 cm/year. He was brought to our pedi-
atric endocrine clinic at the age of 7 years and 
4 months. At that time, his bone age was estimated
at between 3 and 4 years. Evaluation of pituitary
function showed hypopituitarism including GHD,
thyrotropin deficiency, and gonadotropin defi-
ciency. He underwent thyroxine replacement
therapy and remained euthyroid in the following
years. GH therapy was started at the age of 11 years
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and 2 months but was discontinued at the age 
of 12 years and 2 months because of the family’s
financial problems. Magnetic resonance imaging
of the sella taken at the age of 15 years and 6
months showed small pituitary gland, thin stalk,
and ectopic posterior lobe. He restarted GH ther-
apy at the age of 15 years and 6 months, and had
catch-up growth in the following years. GH ther-
apy was discontinued at the age of 19 years and
11 months when his height reached 165.8 cm. At
that time, his body mass index (BMI) was 25.6
kg/m2 and his bone age was estimated to be 13
years and 6 months. Pain over the left hip fol-
lowed by limping gait was noted just before he
stopped GH therapy. Pelvic X-ray examination
showed mild SCFE of the left femur (Figure 1).
He underwent reduction and internal fixation 
of the left femur at the age of 20 years with 
complete recovery.
Case 2
A 17-year-old girl had a craniopharyngioma re-
moved at the age of 2 years. Panhypopituitarism
was noted postoperatively and she underwent 
replacement therapy with thyroxine and cortisone
acetate since the age of 2 years and 2 months.
Retarded growth with a growth rate of 3.5 cm/year
was noted since 6 years and 4 months. However,
GH therapy was initially refused because of pa-
rental concerns about its side effects. At the age of
13 years and 9 months, her parents decided to
accept GH therapy. Her height was 139 cm, and
BMI was 17.1 kg/m2, and her bone age was esti-
mated to be 13 years. She grew 8.3 cm in the fol-
lowing 1 year. However, there was no evidence of
pubertal development then and gonadotropin
deficiency was confirmed by GnRH test. Pain
over the left hip after falling to the ground was
noted when she was 14 years and 10 months old
and severe SCFE was confirmed by plain film of
the left hip joint (Figure 2). She underwent reduc-
tion and internal fixation of the left femur at the
age of 14 years and 11 months, but the procedure
was complicated by the protrusion of the screw
tip into the joint cavity. Chondrolysis followed by
avascular necrosis of the left femoral head was
noted when she was 15 years and 5 months old.
Her height was 151.6 cm when SCFE developed.
Therefore, GH therapy was stopped and estrogen
replacement therapy started postoperatively.
Case 3
A 13-year and 9-month-old boy had bilateral
cryptorchidism, hypotonia, poor feeding, and
psychomotor retardation after birth. PWS was
suspected at the age of 7 months. Hyperphagia
and obesity developed at the age of 7 years. The
diagnosis of PWS was confirmed by the demon-
stration of maternal uniparental disomy of chro-
mosome 15 at the age of 11 years. Endocrine
function evaluation at the age of 12 years and 
9 months showed classic GHD and hypogo-
nadotropic hypogonadism. At that time, his
height was 138.3 cm and BMI was 26.5 kg/m2.
Figure 1. Case 1: pelvic radiograph shows mild displace-
ment of epiphysis between the femoral head and femoral
neck (arrow).
Figure 2. Case 2: pelvic radiograph shows the presence of
severe slipped capital femoral epiphysis (arrow).
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There was no sign of puberty and his bone age was
estimated to be 15 years then. GH therapy was
given at the age of 12 years and 11 months old.
Pain over the right knee was noted after he fell to
the ground 2 months after starting GH therapy.
Pain over the right hip was noted when he was
13 years and 5 months old, and radiographic study
of the right hip joint confirmed the presence of
mild SCFE (Figure 3). Surgical intervention was
advised but his family hesitated. Severe pain over
the right hip was noted when he walked upstairs
in the following 1 month, and radiograph of the
right hip joint showed deterioration of SCFE.
Therefore, reduction and internal fixation of the
right femur were performed when he was 13 years
and 6 months old and he could walk without 
assistance thereafter. As his mother was afraid 
of the risk of recurrence of SCFE, GH therapy 
was discontinued and replacement therapy with
testosterone was started postoperatively.
Discussion
SCFE denotes the displacement of the femoral
head relative to the femoral neck through the
growth plate. SCFE remains one of the most com-
mon hip disorders during adolescence.6,7 The in-
cidence of SCFE in the general population varies
with age, race and geographic location, season,
and from year to year. The annual incidence of
SCFE in the general population of the United
States was reported to be between 2/100,000 and
10/100,000.6,7 Males are more commonly affected
than females.6,7 SCFE usually occurs during the
early adolescent growth spurt, with a peak in boys
aged between 13 and 14 years and girls aged be-
tween 11 and 12 years.6,7 The National Coopera-
tive Growth Study reported that the percentage
of SCFE in children undergoing GH therapy was
between 2.6% and 25.4% of adverse events asso-
ciated with GH therapy2,3 and its annual inci-
dence was estimated to be 59.6/100,000.2,8 These
data suggest that there is an increased risk of
SCFE in children treated with GH.6,7
About 25% of patients with SCFE have a his-
tory of trauma that delivers enough force across
the epiphysis to displace the femoral head.9 A ge-
netic and environmental predisposition has been
considered.10 Obesity may induce SCFE by creat-
ing increased shear forces across the weakened
epiphysis during ambulation.9 Irradiation of the
spine and hips was also considered to be a risk
factor for SCFE.11 SCFE is significantly less com-
monly seen during GH therapy in patients with
idiopathic GHD than those with organic GHD
or Turner syndrome.2 Therefore, some investiga-
tors believe that hormonal imbalance during pu-
berty may weaken the capital femoral epiphysis.12
Harris13 showed that GH weakened and thick-
ened the growth plate, and sex hormone could
strengthen the growth plate in an animal study.
BA
Figure 3. Case 3: pelvic radiograph shows the mild displacement of epiphysis between the femoral head and the
femoral neck (arrow). (A) Anteroposterior view of the pelvis. (B) Frog view of the pelvis. The lesion is more obvious in the
latter view.
Hypogonadism, hypothyroidism, hyperparathy-
roidism, and gigantism have also been reported
to be related to SCFE.12,14,15 Although the patho-
genesis of SCFE is not fully understood, it ap-
pears to be multifactorial.
In the present report, the first two patients
had similar problems of multiple pituitary hor-
mone deficiency and delay in GH therapy until
the teenage years. The first patient was also obese.
It is possible that the combination of multiple
endocrinopathies and rapid growth during GH
therapy at older age may increase the risk of the
development of SCFE. Because obesity and hy-
pogonadism are frequently seen in patients with
PWS, SCFE is presumed to be a common compli-
cation of PWS but this is not true.16 The lower
than expected prevalence of SCFE in patients with
PWS is attributed to the relatively inactive lifestyle
and loss of pubertal growth spurt in these pa-
tients.16 GH therapy in patients with PWS may
alter this situation by inducing change of the
growth plate, rapid growth, and improvement of
physical activity.17 This may partly explain the
development of SCFE in our third patient. Because
the first two patients and their mothers were 
satisfied with their height and the mother of the
third patient was afraid of the risk of recurrence of
SCFE, all three patients stopped GH therapy after
the operation, despite the fact that continuation
of GH therapy is recommended for such cases.1
SCFE is rarely encountered, so early diagnosis
is difficult for many physicians.18 Because the
presentation of SCFE may be subtle, a high index
of suspicion and careful interpretation of hip ra-
diographs are important for early diagnosis.19 As
shown in Figure 3, a frog-lateral view on radiog-
raphy is more sensitive for such a purpose, espe-
cially in patients with mild SCFE. Recognition of
SCFE necessitates urgent orthopedic management
because delay in diagnosis and treatment is asso-
ciated with increased severity of slip.19,20 Outcome
after the surgical treatment depends greatly on
the degree of slip before repair.9,18,19 It has been
reported that a high percentage (between 61%
and 100%) of bilateral SCFE was detected in 
children with endocrinopathies and prophylactic 
internal fixation of the opposite hip in such cases
was advised.12,21 None of our three patients had
such a problem during follow-up.
In conclusion, SCFE is an important compli-
cation during GH therapy in patients with risk
factors such as endocrinopathies and obesity. A
high index of suspicion and careful evaluation of
SCFE is needed when patients complain of a limp,
or pain over the hip and knee during GH therapy.
Long-term outcome may be improved by early
diagnosis and treatment of this complication.
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